帕金森病的致病因素及治疗
Pathogenic Factors and Treatment of Parkinson’s Disease
DOI: 10.12677/BP.2021.114008, PDF,   
作者: 姜育辉：南通大学医学院，江苏 南通；南通大学，教育部/江苏省神经再生重点实验室/神经再生协同创新中心，江苏 南通；刘晓宇, 杨宇民*：南通大学，教育部/江苏省神经再生重点实验室/神经再生协同创新中心，江苏 南通；周胜鸾：南通大学医学院，江苏 南通
关键词: 帕金森病；α-突触核蛋白；运动功能障碍；康复治疗； Parkinson’s Disease； α-Synuclein； Motor Dysfunction； Rehabilitation Therapy
摘要: 帕金森病(Parkinson’s disease, PD)，是继阿兹海默症之后的第二大神经退行性疾病。据统计，全球超过一半的帕金森病患者都是中国人，帕金森病已经成为继心血管疾病、肿瘤之后的我国中老年人的第三杀手。根据起源，该病主要分遗传性和特发性两种。帕金森病患者神经病理学特征常表现为大脑黑质区域多巴胺能神经元的缺失和特定神经元内α-突触核蛋白(α-syn)的沉积。帕金森病主要表现为一系列的运动功能障碍，如震颤、僵直、姿势和步态异常等。帕金森病的发病机理涉及多种因素，如线粒体功能障碍、氧化应激、神经炎症等，现在仍然未有定论，因此也未有药物可以完全的抑制疾病的进程和治愈疾病，现多用左旋多巴和多巴胺激动剂治疗PD，也会辅助一些物理康复治疗。所以，如何在多致病因素的情况下寻找到治疗的有效方法是未来研究中的大挑战，同时也是研究的热点。
Abstract: Parkinson’s disease (PD) is the second largest neurodegenerative disease after Alzheimer’s disease. According to statistics, more than half of the patients with Parkinson’s disease in the world are Chinese. Parkinson’s disease has become the third killer of middle-aged and elderly people in China after cardiovascular diseases and tumors. According to the origin, the disease is mainly divided into hereditary and idiopathic. The neuropathological characteristics of patients with Parkinson’s disease are often manifested in the absence of dopaminergic neurons in the substantia nigra and α-Synuclein deposition in specific neurons. Parkinson’s disease is mainly characterized by a series of motor dysfunction, such as tremor, stiffness, abnormal posture and gait and so on. The pathogenesis of Parkinson’s disease involves many factors, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, etc. There is still no final conclusion. Therefore, there is no drug that can completely inhibit the process of the disease and cure the disease. Now, levodopa and dopamine agonists are used to treat PD, and some physical rehabilitation treatments will also be assisted. Therefore, how to find an effective treatment in the case of multiple pathogenic factors is not only a great challenge in future research, but also a research hotspot.
文章引用：姜育辉, 刘晓宇, 周胜鸾, 杨宇民. 帕金森病的致病因素及治疗[J]. 生物过程, 2021, 11(4): 67-75. https://doi.org/10.12677/BP.2021.114008

参考文献

[1] Pringsheim, T., Jette, N., Frolkis, A. and Steeves, T.D. (2014) The Prevalence of Parkinson’s Disease: A Systematic Re-view and Meta-Analysis. Movement Disorders, 29, 1583-1590. [Google Scholar] [CrossRef] [PubMed]
[2] Parkinson, J. (2002) An Essay on the Shaking Palsy. Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223-236. [Google Scholar] [CrossRef] [PubMed]
[3] Allegri, R.F., Bartoloni, L. and Sica, R.E. (2016) History of the Depart-ment of Neurology at the University of Buenos Aires (1887-2007). Vertex, 27, 306-318.
[4] Baldereschi, M., Di, C.A., Rocca, W.A., Vanni, P., Maggi, S., Perissinotto, E., et al. (2000) Parkinson’s Disease and Parkinsonism in a Longitudi-nal Study: Two-Fold Higher Incidence in Men. Neurology, 55, 1358-1363. [Google Scholar] [CrossRef] 
[5] Jankovic, J. (2008) Parkinson’s Disease: Clinical Features and Diag-nosis. Journal of Neurology Neurosurgery & Psychiatry, 79, 368-376. [Google Scholar] [CrossRef] [PubMed]
[6] Halliday, G.M., Holton, J.L., Revesz, T. and Dickson, D.W. (2011) Neuropathology Underlying Clinical Variability in Patients with Synucleinopathies. Acta Neuropathologica, 122, 187-204. [Google Scholar] [CrossRef] [PubMed]
[7] Damier, P., Hirsch, E.C., Agid, Y. and Graybiel, A.M. (1999) The Substantia Nigra of the Human Brain. II. Patterns of Loss of Dopamine-Containing Neurons in Parkinson’s Disease. Brain, 122, 1437-1448. [Google Scholar] [CrossRef] [PubMed]
[8] Dijkstra, A.A., Voorn, P., Berendse, H.W., Groenewegen, H.J., Rozemuller, A.J. and van de Berg, W.D. (2014) Stage-Dependent Nigral Neuronal Loss in Incidental Lewy Body and Parkinson’s Disease. Movement Disorders, 29, 1244-1251. [Google Scholar] [CrossRef] [PubMed]
[9] Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H. and Braak, E. (2003) Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiology of Aging, 24, 197-211. [Google Scholar] [CrossRef] 
[10] Iacono, D., Geraci-Erck, M., Rabin, M.L., Adler, C.H., Ser-rano, G., Beach, T.G., et al. (2015) Parkinson Disease and Incidental Lewy Body Disease: Just a Question of Time? Neurology, 85, 1670-169. [Google Scholar] [CrossRef] 
[11] Chaudhuri, K.R. and Schapira, A.H. (2009) Non-Motor Symptoms of Parkinson’s Disease: Dopaminergic Pathophysiology and Treatment. Lancet Neurology, 8, 464-474. [Google Scholar] [CrossRef] 
[12] PD MED Collaborative Group (2014) Long-Term Effec-tiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinson’s Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial. Lancet, 384, 1196-1205. [Google Scholar] [CrossRef] 
[13] Mahlknecht, P., Gasperi, A., Willeit, P., Kiechl, S., Stockner, H., Willeit, J., et al. (2016) Prodromal Parkinson’s Disease as Defined per MDS Research Criteria in the General Elderly Community. Movement Disorders, 31, 1405-1408. [Google Scholar] [CrossRef] [PubMed]
[14] Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., et al. (2010) Physical Activities and Future Risk of Parkinson Disease. Neurology, 75, 341-348. [Google Scholar] [CrossRef] 
[15] Yang, F., Trolle Lagerros, Y., Bellocco, R., Adami, H.-O., Fang, F., Pedersen, N.L., et al. (2014) Physical Activity and Risk of Parkinson’s Disease in the Swedish National March Cohort. Brain, 138, 269-275. [Google Scholar] [CrossRef] [PubMed]
[16] Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, A., Bloch, D.A., et al. (2003) Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity. American Journal of Epidemiology, 157, 1015-1022. [Google Scholar] [CrossRef] [PubMed]
[17] Pinter, B., Diemzangerl, A., Wenning, G.K., Scherfler, C., Oberaigner, W., Seppi, K., et al. (2015) Mortality in Parkinson’s Disease: A 38-Year Follow-Up Study. Movement Disorders, 30, 819-825. [Google Scholar] [CrossRef] [PubMed]
[18] Gjerstad, M.D., Wentzel-Larsen, T., Aarsland, D. and Larsen, J.P. (2007) Insomnia in Parkinson’s Disease: Frequency and Progression over Time. Journal of Neurology, Neurosur-gery, and Psychiatry, 78, 476-479. [Google Scholar] [CrossRef] [PubMed]
[19] Morens, D.M., Davis, J.W., Grandinetti, A., Ross, G.W., Popper, J.S. and White, L.R. (1996) Epidemiologic Observations on Parkinson’s Disease Incidence and Mortality in a Prospec-tive Study of Middle-Aged Men. Neurology, 46, 1044-1050. [Google Scholar] [CrossRef] 
[20] Payami, H. and Zareparsi, S. (1973) Epidemiology of Parkinson’s Disease. Lancet Neurology, 66, 202-203.
[21] Xiong, N., Long, X., Xiong, J., Jia, M., Chen, C., Huang, J., et al. (2012) Mitochondrial Complex I Inhibitor Rotenone-Induced Toxicity and Its Potential Mechanisms in Parkinson’s Disease Models. Critical Reviews in Toxicology, 42, 613-632. [Google Scholar] [CrossRef] [PubMed]
[22] Ascherio, A. and Schwarzschild, M.A. (2016) The Epidemi-ology of Parkinson’s Disease: Risk Factors and Prevention. Lancet Neurology, 15, 1257-1272. [Google Scholar] [CrossRef] 
[23] Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., et al. (2014) Large-Scale Meta-Analysis of Genome-Wide Association Data Identifies Six New Risk Loci for Parkinson’s Disease. Nature Genetics, 46, 989-993. [Google Scholar] [CrossRef] [PubMed]
[24] 马敬红, 陈彪. 帕金森病患者发病年龄与临床异质性的回顾性分析[J]. 中国临床康复, 2005, 9(17): 10-12.
[25] Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H.J. and Stefanis, L. (2011) Pathological Roles of α-Synuclein in Neurological Disorders. Lancet Neurology, 10, 1015-1025. [Google Scholar] [CrossRef] 
[26] Xilouri, M., Brekk, O.R. and Stefanis, L. (2013) Al-pha-Synuclein and Protein Degradation Systems: a Reciprocal Relationship. Molecular Neurobiology, 47, 537-551. [Google Scholar] [CrossRef] [PubMed]
[27] Chu, Y. and Kordower, J.H. (2007) Age-Associated Increases of α-Synuclein in Monkeys and Humans Are Associated with Nigrostriatal Dopamine Depletion: Is This the Target for Par-kinson’s Disease? Neurobiology of Disease, 25, 134-149. [Google Scholar] [CrossRef] [PubMed]
[28] Buneeva, O.A. and Medvedev, A.E. (2011) Mitochondrial Dys-function in Parkinson’s Disease. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 5, 313-336. [Google Scholar] [CrossRef] 
[29] Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G. and Anandatheerthavarada, H.K. (2008) Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain. Journal of Biological Chemistry, 283, 9089-9100. [Google Scholar] [CrossRef] 
[30] Telford, J.E., Kilbride, S.M. and Davey, G.P. (2009) Complex I Is Rate-Limiting for Oxygen Consumption in the Nerve Terminal. Journal of Biological Chemistry, 284, 9109-9114. [Google Scholar] [CrossRef] 
[31] Dias, V., Junn, E. and Mouradian, M.M. (2013) The Role of Oxida-tive Stress in Parkinson’s Disease. Journal of Parkinson’s Disease, 3, 461-491. [Google Scholar] [CrossRef] 
[32] Di, N.M., Masciullo, M., Verrigni, D., Petrillo, S., Modoni, A., Rizzo, V., et al. (2016) DJ-1 Modulates Mitochondrial Response to Oxidative Stress: Clues from a Novel Diagnosis of PARK7. Clinical Genetics, 92, 18-25. [Google Scholar] [CrossRef] [PubMed]
[33] Guzman, J.N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P.T., et al. (2010) Oxidant Stress Evoked by Pacemaking in Dopaminergic Neurons Is Attenuated by DJ-1. Nature, 468, 696-700. [Google Scholar] [CrossRef] [PubMed]
[34] Surmeier, D.J., Schumacker, P.T., Guzman, J.D., Ilijic, E., Yang, B. and Zampese, E. (2016) Calcium and Parkinson’s Disease. Biochemical & Biophysical Research Communications, 483, 1013-1019. [Google Scholar] [CrossRef] [PubMed]
[35] Moehle, M.S. and West, A.B. (2015) M1 and M2 Immune Acti-vation in Parkinson’s Disease: Foe and Ally? Neuroscience, 302, 59-73. [Google Scholar] [CrossRef] [PubMed]
[36] Ransohoff, R.M. (2016) How Neuroinflammation Con-tributes to Neurodegeneration. Science, 353, 777-783. [Google Scholar] [CrossRef] [PubMed]
[37] Ma, B., Xu, L., Pan, X., Sun, L., Ding, J., Xie, C., et al. (2015) LRRK2 Modulates Microglial Activity through Regulation of Chemokine (C–X3–C) Receptor 1-Mediated Signaling Pathways. Human Molecular Genetics, 25, 3515-3523. [Google Scholar] [CrossRef] [PubMed]
[38] Hirsch, E.C. and Hunot, S. (2009) Neuroinflammation in Parkinson’s Disease: A Target for Neuroprotection? Lancet Neurology, 8, 382-397. [Google Scholar] [CrossRef] 
[39] Gao, H.M., Kotzbauer, P.T., Uryu, K., Leight, S., Trojan-owski, J.Q. and Lee, V.M.-Y. (2008) Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminer-gic Neurodegeneration. Journal of Neuroscience, 28, 7687-7698. [Google Scholar] [CrossRef] 
[40] George, S. and Brundin, P. (2015) Immunotherapy in Parkinson’s Disease: Micromanaging α-Synuclein Aggregation. Journal of Parkinson’s Disease, 5, 413-424. [Google Scholar] [CrossRef] 
[41] Oksanen, M., Lehtonen, S., Jaronen, M., Goldsteins, G., Hämäläinen, R.H. and Koistinaho, J. (2019) Astrocyte Alterations in Neurodegenerative Pathologies and Their Modeling in Human Induced Pluripotent Stem Cell Platforms. Cellular and Molecular Life Sciences, 76, 2739-2760. [Google Scholar] [CrossRef] [PubMed]
[42] Rocha, N.P., De Miranda, A.S. and Teixeira, A.L. (2015) In-sights into Neuroinflammation in Parkinson’s Disease: From Biomarkers to Anti-Inflammatory Based Therapies. BioMed Research International, 2015, Article ID: 628192. [Google Scholar] [CrossRef] [PubMed]
[43] Tang, Y. and Le, W. (2016) Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Molecular Neurobiology, 53, 1181-1194. [Google Scholar] [CrossRef] [PubMed]
[44] Rojanathammanee, L., Murphy, E.J. and Combs, C.K. (2011) Expression of Mutant α-Synuclein Modulates Microglial Phenotype in Vitro. Journal of Neuroinflammation, 8, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[45] Lewitt, P.A. and Fahn, S. (2016) Levodopa Therapy for Par-kinson Disease: A Look Backward and Forward. Neurology, 86, S3-S12. [Google Scholar] [CrossRef] 
[46] Cenci, M.A. (2014) Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Frontiers in Neurology, 5, Ar-ticle No. 242. [Google Scholar] [CrossRef] [PubMed]
[47] Ferreira, J.J., Lees, A., Rocha, J.F., Poewe, W., Rascol, O., Soares-da-Silva, P., et al. (2016) Opicapone as an Adjunct to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Motor Fluctuations: A Randomised, Double-Blind, Controlled Trial. Lancet Neurology, 15, 154-165. [Google Scholar] [CrossRef] 
[48] Schapira, A.H. (2011) Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease: A Review of Symptomatic and Potential Disease-Modifying Effects. CNS Drugs, 25, 1061-1071. [Google Scholar] [CrossRef] [PubMed]
[49] Birkmayer, W., Riederer, P., Ambrozi, L. and Youdim, M.B.H. (1977) Implications of Combined Treatment with ‘Madopar’ and L-Deprenil in Parkinson’s Disease: A Long-Term Study. Lancet, 1, 439-443. [Google Scholar] [CrossRef] 
[50] Connolly, B.S. and Lang, A.E. (2014) Pharmacological Treatment of Parkinson Disease: A Review. JAMA, 311, 1670-1683. [Google Scholar] [CrossRef] [PubMed]
[51] Jankovic, J. and Poewe, W. (2012) Therapies in Parkinson’s Disease. Current Opinion in Neurology, 25, 433-447. [Google Scholar] [CrossRef] 
[52] Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J.-F., Perret, J.E., et al. (1995) Effect on Parkinsonian Signs and Symptoms of Bilateral Subthalamic Nucleus Stim-ulation. Lancet, 345, 91-95. [Google Scholar] [CrossRef] 
[53] Bronstein, J.M., Tagliati, M., Alterman, R.L., Lozano, A.M., Volkmann, J., Stefani, A., et al. (2011) Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Re-view of Key Issues. Archives of Neurology, 68, 165. [Google Scholar] [CrossRef] [PubMed]
[54] Voges, J., Hilker, R.B., Tzel, K., Kiening, K.L., Kloss, M., Kup-sch, A., et al. (2007) Thirty days Complication Rate Following Surgery Performed for Deep-Brain-Stimulation. Move-ment Disorders, 22, 1486-1489. [Google Scholar] [CrossRef] [PubMed]
[55] Li, W., Chen, S. and Li, J.Y. (2015) Human Induced Pluripotent Stem Cells in Parkinson’s Disease: A Novel Cell Source of Cell Therapy and Disease Modeling. Progress in Neurobiology, 134, 161-177. [Google Scholar] [CrossRef] [PubMed]
[56] Chen, Z. (2015) Cell Therapy for Parkinson’s Disease: New Hope from Reprogramming Technologies. Aging & Disease, 6, 499-503. [Google Scholar] [CrossRef] 
[57] Kim, D., Kim, C.H., Moon, J.I., Chung, Y.G., Chang, M.Y., Han, B.S., et al. (2009) Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. Cell Stem Cell, 4, 472-476. [Google Scholar] [CrossRef] [PubMed]
[58] Kirkeby, A., Grealish, S., Wolf, D.A., Nelander, J., Wood, J., Lundblad, M., et al. (2012) Generation of Regionally Specified Neural Progenitors and Functional Neurons from Human Embryonic Stem Cells under Defined Conditions. Cell Reports, 1, 703-714. [Google Scholar] [CrossRef] [PubMed]
[59] Barker, R.A., Barrett, J., Mason, S.L. and Björklund, A. (2013) Fetal Dopaminergic Transplantation Trials and the Future of Neural Grafting in Parkinson’s Disease. Lancet Neurology, 12, 84-91. [Google Scholar] [CrossRef] 
[60] Bloem, B.R., De Vries, N.M. and Ebersbach, G. (2015) Nonpharmacological Treatments for Patients with Parkinson’s Disease. Movement Disorders, 30, 1504-1520. [Google Scholar] [CrossRef] [PubMed]
[61] Keus, S.H., Munneke, M., Nijkrake, M.J., Kwakkel, G. and Bloem, B.R. (2009) Physical Therapy in Parkinson’s Disease: Evolution and Future Challenges. Movement Disorders, 24, 1-14. [Google Scholar] [CrossRef] [PubMed]
[62] Schrag, A., Jahanshahi, M. and Quinn, N. (2000) What Contributes to Quality of Life in Patients with Parkinson’s Disease? Journal of Neurology Neurosurgery & Psychiatry, 69, 308-312. [Google Scholar] [CrossRef] [PubMed]
[63] de Lau, L.M. and Breteler, M.M. (2006) Epidemiology of Parkinson Disease. Lancet Neurology, 5, 525-535. [Google Scholar] [CrossRef] [PubMed]